NATCO Pharma Limited
Valuation (94/100) does the heavy lifting; financial trend (0/100) is the drag.
Buy zoneNATCO Pharma Limited earns a Hold from StocksWizard, with a blended score of 53/100. At ₹917 it trades below our blended DCF and relative-multiples fair value of ₹1,834, about 100% upside to that estimate — we read it as undervalued by 100%. On 11.3x trailing earnings it sits cheaper than the Healthcare median of about 37.6x. The price is about 24% below its 52-week high of ₹1,206 and 16% above the low of ₹790.18. Financial health scores 100/100, in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9. The average analyst target of ₹1,021.22 implies about 11% upside across 9 analysts. It clears 8 of 13 investability checks, with durability 71, valuation 88 and momentum 15 on our 0–100 scales.
Analysis by Ankit Sharma · StocksWizard's own estimates from end-of-day public data — see how we calculate them. For information only, not investment advice.
With a 20% margin of safety, our buy-below price is ₹1,467.2. Low-confidence estimate — limited data.
Analyst views
1-year price
EOD · 2026-07-3152-week range
-23.96% from the 52-week high.
Price above both moving averages reads as an intact uptrend; below both, the trend is against you.
Verdict pillars
Hold53Piotroski F-score 4/9 — quality of earnings & balance sheet.
Our scores
Durability rewards strong, low-debt, profitable businesses; Valuation rewards stocks cheap vs their sector; Momentum rewards strong price trends.
Investability checklist
- Pass: ROE above 15%: 16.9%
- Pass: Low debt (D/E < 0.5): 0.08x
- Pass: Positive free cash flow
- Fail: Revenue growth > 10%: -40%
- Fail: Earnings growing: -34%
- Pass: Net margin ≥ 10%: 34.8%
- Pass: Current ratio > 1.5: 3.01
- Pass: Below our fair value
- Pass: Margin of safety ≥ 20%
- Fail: Above 200-day average
- Fail: Above 50-day average
- No data: Positive 1-year return
- Pass: Altman Z in safe zone: Z 6.71
- Fail: Piotroski ≥ 7: 4/9
Quarterly results
Annual financials
Shareholding
- Promoter51.0%
- Institutions12.4%
- Public & other36.5%
Promoter holding via insider stake; institutional via reported holdings.
Key fundamentals
Bull case vs bear case
Bull case
Strengths
- Lightly leveraged balance sheet.
- Healthy profit margin (34.8%).
- Financially solid — Altman Z 6.71.
Opportunities
- Trading in our value buy zone versus sector peers.
- Trades ~100% below our estimated fair value.
Bear case
Weaknesses
- Price below its 200-day moving average (downtrend).
Threats
- Earnings contracting year on year.
About NATCO Pharma Limited
NATCO Pharma Limited develops, manufactures, and markets pharmaceutical formulations and active pharmaceutical ingredients across oncology, central nervous system, and pain management categories. The company operates in India, the United States, and internationally, offering finished dosage formulations for cancers including blood, liver, kidney, lung, brain, breast, and ovary cancers, along with APIs and intermediates.
NATCO Pharma Limited — frequently asked questions
Is NATCO Pharma Limited a buy, hold or sell?
StocksWizard currently rates NATCO Pharma Limited (NATCOPHARM) a Hold, based on a blended score of 53/100 across valuation, quality, momentum and price trend. This is our own model-based view, not investment advice.
What is NATCO Pharma Limited's fair value?
Our blended DCF and relative-valuation model estimates NATCO Pharma Limited's fair value at about ₹1,834, versus a current price of ₹917 — roughly 100% upside. On that basis the stock looks undervalued by 100%.
Is NATCO Pharma Limited financially healthy?
NATCO Pharma Limited scores 100/100 on our financial-health model, placing it in the safe band on the Altman Z-score, with a Piotroski F-score of 4/9.
How has NATCO Pharma Limited's share price performed?
NATCO Pharma Limited is down 18% over three months, and last traded at ₹917. Past performance doesn't predict future returns.
More in Healthcare
View allOur verdict, fair value, financial-health and checklist are StocksWizard's own estimates, computed from public end-of-day data using standard models (DCF, relative valuation, Altman Z, Piotroski). For information only — not investment advice or a recommendation. Verify independently before investing.